openPR Logo
Press release

Increase in Prevalence of Respiratory Diseases Serves as a Major Driving Factor for the Digital Dose Inhaler Market by 2024

05-25-2017 03:34 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

Increase in Prevalence of Respiratory Diseases Serves as a Major

Customer-centric health care systems and the development of new treatment regimens can potentially disrupt the entire health care system. Digital dose inhalers are commonly known as digihalers. Digital dose inhalers are the type of inhalers which enable patients to track the number of doses that have been consumed. This is expected to enable doctors to track prescribed therapy regime and patients adherence toward it.

Browse through Digital Dose Inhaler Market report to know what factors will shape the market by 2024: http://www.transparencymarketresearch.com/digital-dose-inhaler-market.html

Generally, the number of medicine puffs in a standard inhaler is 120. The digital dose inhaler comes with a small screen to display the remaining puffs/doses discounting from 120. This feature is likely to help patients to remind them that they have taken medication or not. This technological advancement in the conventional and commonly used inhalers such as MDIs and DPIs is expected to take the respiratory devices market to a higher level in health care digitalization.

The most preferred inhalers are metered dose inhalers and dry powder inhalers. The metered dose inhalers segment accounts for a large market share. The digital dry powder inhalers segment is expected to grow in the near future. These next generation digital dose inhalers provide accurate dose counter information as well as low dose warning indicator for asthma and COPD patients which serve as the major factor for pulling patient pool toward it. This in turn is driving the market.

The global digital dose inhaler market is segmented on the basis of product type, application, and geography. On the basis of product type, the market is segmented as metered dose inhaler and dry powder inhaler. The metered dose inhaler segment is contributing a larger share in this market due to its convenience and non-breath-activated doses. Increase in geriatric population across the globe is expected to drive demand for digital dose inhaler devices as the risk of respiratory disease is higher among the geriatric population. Some digital dose inhalers can capture details such as the time and location during which the patient has used asthma medication, and this information is stored and wirelessly transmitted to a user’s smartphone or server. These systems use a combination of sensors, mobile apps, analytics, and individualized feedback.

By application, the digital dose inhaler market is segmented into asthma, COPD, cystic fibrosis, and others. The asthma and COPD segments capture a significant share of the digital dose inhaler market. The chronic respiratory disorders such as asthma and COPD are becoming more prominent, causing disability and death with the increasing aging population. According to the Forum of International Respiratory Societies (FIRS), COPD affects more than 200 million people and is projected to be the fourth leading cause of death in the world by 2030, while asthma affects about 235 million people worldwide. This increase in prevalence of respiratory diseases serves as a major driving factor for the market.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are likely to dominate the market of digital dose inhaler. Rise in geriatric population and high per capita income are projected to propel the market in North America. Increase in adoption of personalized health technologies is one of the key factors driving the market of digital dose inhaler during the forecast period. It is followed by Europe, accounting for a large share of the market. Asia Pacific is the most progressive region for the digital dose inhaler market. The increase in health care awareness and per capita income are estimated to drive the market in Asia Pacific.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Digital Dose Inhaler Market by 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18881

Major players of the digital dose inhaler market are Glenmark Pharmaceuticals Ltd., Novartis A/S, Propeller Health, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Philips Respironics.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Increase in Prevalence of Respiratory Diseases Serves as a Major Driving Factor for the Digital Dose Inhaler Market by 2024 here

News-ID: 550911 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for COPD

Copd CBD Gummies: Reviews (Shocking Facts) Copd CBD Oil "Ingredients" Pain Relie …
Copd CBD Gummies: With the increasing need for both individual and expert degrees, the stress and also stress are also enhancing. Individuals are using various methods to fight it. However, as a result of much less time for self, it is really hard. Here the natural herbs and supplements have actually discovered their way into our lives. The Copd CBD Oil are instances of super-effective natural supplements. The CBD existing
Power Harmonica to Cure Chronic Asthma & COPD
Power Harmonica is a free reed wind musical instrument. It is small rectangular shaped musical instrument. It has 48 number of holes which makes it special and different from other harmonica's. It's a pocket-friendly musical instrument. Power Harmonica is used as a natural treatment for many types of lung disorders and has no side effects. To play Power Harmonica there is no need of having a musical background it can be
COPD Therapeutics Global Market Research Report 2019
COPD Therapeutics Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/copd-therapeutics-market/80858 The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications and market
Global COPD and Asthma Devices Market Size
According to a new report, Global COPD and Asthma Devices Market, published by KBV Research, The Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 – 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would
COPD Drug Market Opportunity & Clinical Pipeline Analysis
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the
04-10-2017 | Health & Medicine
TMR
Asthma and COPD Drugs Market: High Costs of Asthma and COPD Drugs and Consumer A …
Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell that vary in severity and frequency. COPD is a disease of the lungs characterized by obstruction to airflow that interferes with normal breathing. According to the WHO, COPD accounted for over 3 million deaths in 2012, which is equal to 6% of all deaths globally in that year. Moreover, the